Monique R Bidell
Overview
Explore the profile of Monique R Bidell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reveles K, Gonzales-Luna A, Golan Y, Alonso C, Guthmueller B, Tan X, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae341.
PMID: 39006315
Background: Antibiotic use is a major risk factor for recurrent infection (CDI) due to the associated disruption in gut microbiota. Fecal microbiota, live-jslm (REBYOTA®; RBL, previously RBX2660), is the first...
2.
Feuerstadt P, Crawford C, Tan X, Pokhilko V, Bancke L, Ng S, et al.
J Clin Gastroenterol
. 2023 Nov;
58(8):818-824.
PMID: 38019088
Goals: To assess fecal microbiota, live-jslm (REBYOTA, abbreviated as RBL, formerly RBX2660) efficacy and safety in participants grouped by recurrent Clostridioides difficile infection (rCDI) risk factors and treatment-related variables. Background:...
3.
Bidell M, Hobbs A, Lodise T
Pharmacotherapy
. 2022 Sep;
42(11):849-857.
PMID: 36168753
The gut microbiome has been referred to as the "forgotten organ." Although much about the gut microbiome remains incompletely understood, data on its clinical importance is emerging at rapid speed....
4.
Molleti R, Bidell M, Tatara A
J Pharm Pract
. 2022 Sep;
36(4):993-997.
PMID: 36112954
PurposeWe report a probable case of morbilliform drug eruption secondary to fidaxomicin in a patient with infection (CDI). A 62-year-old female presented to our institution's emergency department (ED) with symptoms...
5.
Monk M, Elshaboury R, Tatara A, Nelson S, Bidell M
Microbiol Spectr
. 2022 May;
10(3):e0038422.
PMID: 35543561
This case series describes seven patients who received rifabutin in place of rifampin combined with conventional antimicrobial therapy for treatment of hardware-associated staphylococcal infections. Infection recurrence, defined as need for...
6.
Atallah N, Warren H, Roberts M, Elshaboury R, Bidell M, Gandhi R, et al.
PLoS One
. 2022 Jan;
17(1):e0262342.
PMID: 35025929
Purpose: Coronavirus disease-2019 (COVID-19) is associated with a wide spectrum of clinical symptoms including acute respiratory failure. Biomarkers that can predict outcomes in patients with COVID-19 can assist with patient...
7.
Elshaboury R, Monk M, Bebell L, Bidell M, Adamsick M, Gandhi R, et al.
Ther Adv Infect Dis
. 2021 Sep;
8:20499361211046669.
PMID: 34589214
Background: Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV...
8.
Bidell M, Lodise T
Pharmacotherapy
. 2021 Sep;
41(11):915-931.
PMID: 34558677
Oral tetracyclines have been used in clinical practice for over 60 years. One of the most common indications for use of oral tetracyclines is for treatment of adult outpatients with...
9.
Eljaaly K, Bidell M, Gandhi R, Alshehri S, Enani M, Al-Jedai A, et al.
Open Forum Infect Dis
. 2021 Feb;
8(2):ofab026.
PMID: 33623807
Background: Nephrotoxicity is a known adverse effect of polymyxin antibiotics, including colistin. Although previous meta-analyses have aimed to characterize colistin-associated nephrotoxicity risk relative to other antibiotics, included studies were observational...
10.
ODonnell J, Novak G, Bratek B, Singh G, Duru O, Mitchell C, et al.
Int J Antimicrob Agents
. 2021 Feb;
57(4):106311.
PMID: 33621602
Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality. Oral vancomycin is a cornerstone of CDI treatment, but dosing strategies in clinical practice may differ from guideline...